Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B
暂无分享,去创建一个
J. Cheong | S. Cho | H. Cho | Soon Sun Kim | Seon Joo Ahn | Joo Han Park
[1] Sheng-Nan Lu,et al. Antiviral effect of entecavir in nucleos(t)ide analogue‐naïve and nucleos(t)ide analogue‐experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy , 2014, Journal of viral hepatitis.
[2] L. Gao,et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg‐positive chronic hepatitis B patients with high HBV DNA , 2014, Alimentary pharmacology & therapeutics.
[3] I. Kim,et al. Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response , 2013, Gut and liver.
[4] T. Asselah,et al. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. , 2013, Clinics in liver disease.
[5] Jie Luo,et al. Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life , 2013, International journal of medical sciences.
[6] Soon Sun Kim,et al. Multidrug‐resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy , 2013, Journal of medical virology.
[7] D. Sinn,et al. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. , 2012, World journal of gastroenterology.
[8] W. Choe,et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy , 2012, Scandinavian journal of gastroenterology.
[9] Huy A. Nguyen,et al. Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders , 2012, Digestive Diseases and Sciences.
[10] C. Bunchorntavakul,et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir , 2012, Journal of viral hepatitis.
[11] F. Zoulim,et al. Management of treatment failure in chronic hepatitis B. , 2012, Journal of hepatology.
[12] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.
[13] M. Buti,et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response , 2011, Hepatology.
[14] M. Osborn. Safety and efficacy of entecavir for the treatment of chronic hepatitis B , 2011, Infection and drug resistance.
[15] J. Cheong,et al. Low efficacy of entecavir therapy in adefovir‐refractory hepatitis B patients with prior lamivudine resistance , 2010, Journal of viral hepatitis.
[16] T. Berg,et al. Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.
[17] Ronald E. Rose,et al. Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.
[18] M. Ghany,et al. Antiviral resistance and hepatitis B therapy , 2009, Hepatology.
[19] R. D. de Man,et al. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir , 2008, European journal of gastroenterology & hepatology.
[20] George Kitis,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.
[21] N. Kim,et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. , 2004, Journal of hepatology.
[22] M. Yuen,et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.